Beyond The Numbers: 4 Analysts Discuss Gritstone Bio Stock
In the latest quarter, 4 analysts provided ratings for Gritstone Bio (NASDAQ:GRTS), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $5.0, with a high estimate of $7.00 and a low estimate of $4.00. A decline of 9.09% from the prior average price target is evident in the current average.
Diving into Analyst Ratings: An In-Depth Exploration
The standing of Gritstone Bio among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Sean Lee | HC Wainwright & Co. | Lowers | Buy | $4.00 | $7.00 |
| Roy Buchanan | JMP Securities | Raises | Market Outperform | $5.00 | $4.00 |
| Sean Lee | HC Wainwright & Co. | Maintains | Buy | $7.00 | - |
| Roy Buchanan | JMP Securities | Announces | Market Outperform | $4.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Gritstone Bio. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gritstone Bio compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Gritstone Bio's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Gritstone Bio's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Gritstone Bio analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Gritstone Bio
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, and CORAL, among others.
Financial Milestones: Gritstone Bio's Journey
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Challenges: Gritstone Bio's revenue growth over 3 months faced difficulties. As of 31 December, 2023, the company experienced a decline of approximately -97.81%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Gritstone Bio's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -106268.97%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Gritstone Bio's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -48.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Gritstone Bio's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -16.89%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Gritstone Bio's debt-to-equity ratio stands notably higher than the industry average, reaching 2.02. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Understanding the Relevance of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.